SQLite Web: event_store.db

Update row sig_39bcbdefa89c in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/where-will-pfizer-stock-be-3-years","as_of":"2026-04-18T17:18:47.705432+00:00","canonical_url":"https://www.fool.com/investing/2026/04/18/where-will-ticker-stock-be-in-3-years/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/where-will-pfizer-stock-be-3-years","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_d82d9ab6e79fe4bd","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/18/where-will-ticker-stock-be-in-3-years/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-18T17:48:24.041874+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsPfizer is facing patent cliffs on multiple drugs in the next few years.","fetched_title":"Where Will Pfizer Stock Be in 3 Years? | Nasdaq","final_url":"https://www.nasdaq.com/articles/where-will-pfizer-stock-be-3-years","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/where-will-pfizer-stock-be-3-years","source_event_id":"evt_29fb8c15b15a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"8a9393f6c1b19e17","kind":"unusual_volume","published_at":"2026-04-18T16:20:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":["2022","2023","last year","2025","2030","five years","next three years","December 17, 2004","April 15, 2005"],"entities":[{"asset_class":"equity","name":"Pfizer","relevance":"high","symbol":"PFE","type":"company"},{"asset_class":"person","name":"Albert Bourla","relevance":"medium","symbol":"","type":"person"},{"asset_class":"equity","name":"Seagen","relevance":"medium","symbol":"","type":"company"},{"asset_class":"equity","name":"Metsera","relevance":"medium","symbol":"","type":"company"},{"asset_class":"drug","name":"Eliquis","relevance":"high","symbol":"","type":"drug"},{"asset_class":"drug","name":"Ibrance","relevance":"high","symbol":"","type":"drug"},{"asset_class":"drug","name":"Xtandi","relevance":"high","symbol":"","type":"drug"},{"asset_class":"drug","name":"Xeljanz","relevance":"high","symbol":"","type":"drug"}],"event_type":"other","information_gaps":["This signal is labeled discovery_unusual_volume_delta, but the provided text contains no volume ratio, baseline volume, or unusual-volume confirmation details.","No explicit statement confirms whether the unusual volume (if any) is driven by news; the article content is about long-term outlook rather than a specific volume event.","The article does not provide a specific 3-year stock price target or forecast level; it discusses business prospects and valuation qualitatively.","No explicit catalyst is tied to a volume spike; the most likely catalyst hypothesis from the text is macro/sector narrative around patent cliffs plus company-specific acquisitions and pipeline progress, but this is not linked to volume data."],"key_facts":["Pfizer is described as facing patent cliffs on multiple drugs including Eliquis, Ibrance, Xtandi, Xeljanz, and other products.","The article states that in 2022 CEO Albert Bourla projected Pfizer might lose up to $18 billion in revenue from 2025 through 2030 due to competition from generics.","The article states Bourla planned to bolster Pfizer\u2019s top line by as much as $25 billion.","The article states Pfizer\u2019s most high-profile acquisition was a $43 billion acquisition of Seagen in 2023.","The article states Pfizer bought Metsera last year for up to $10 billion.","The article states Metsera is developing GLP-1 drugs and could potentially make Pfizer a major player in the anti-obesity market.","The article claims Pfizer generated a strong profit margin of more than 12% last year.","The article states Pfizer has over 100 drug candidates in its pipeline.","The article states Pfizer\u2019s stock has declined by close to 30% over five years.","The article states Pfizer is trading at nine times its expected future profits (based on analyst expectations)."],"numeric_claims":[{"label":"Revenue loss projection (2025-2030)","value":"up to $18 billion"},{"label":"Top-line bolstering plan","value":"up to $25 billion"},{"label":"Seagen acquisition price","value":"$43 billion"},{"label":"Metsera acquisition price","value":"up to $10 billion"},{"label":"Profit margin","value":"more than 12%"},{"label":"Stock decline over five years","value":"close to 30%"},{"label":"Valuation multiple","value":"9x expected future profits"}],"primary_claim":"Pfizer is expected to face heavy sales declines from patent cliffs for multiple drugs over the next few years, but management plans to offset losses via acquisitions and development.","relevance_score":0.35,"sentiment":"mixed","source_quality":"high","summary":"The article argues Pfizer (PFE) faces major revenue declines from upcoming patent cliffs but may offset them through acquisitions and a pipeline, potentially improving the business over the next three years.","topics":["patent cliffs","revenue decline","acquisitions","pipeline","GLP-1/anti-obesity","valuation","stock performance","Motley Fool Stock Advisor"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsPfizer is facing patent cliffs on multiple drugs in the next few years.","tickers":[],"title":"Where Will Pfizer Stock Be in 3 Years?","url":"https://www.fool.com/investing/2026/04/18/where-will-ticker-stock-be-in-3-years/"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel